Long noncoding RNA SNHG12 is a potential diagnostic and prognostic biomarker in various tumors

Chinese Neurosurgical Journal

Jian Zhang¹  Xu Hou²  Xin Chen²  Ligang Wang²  Qiuyi Jiang²  Quan Yang²  Lixiang Wang²  Dayong Han²  Xinzhuang Wang²  Shiguang Zhao³  Jianing Wu⁴  Cheng Zhang⁵ 

[1] Department of General Surgery, The First Affiliated Hospital of Harbin Medical University, Harbin, China;Department of Neurosurgery, First Affiliated Hospital of Harbin Medical University, 150001, Harbin, Heilongjiang Province, China;Key Colleges and Universities Laboratory of Neurosurgery in Heilongjiang Province, 150001, Harbin, Heilongjiang Province, China;Institute of Neuroscience, Sino-Russian Medical Research Center, Harbin Medical University, 150001, Harbin, Heilongjiang Province, China;Department of Neurosurgery, First Affiliated Hospital of Harbin Medical University, 150001, Harbin, Heilongjiang Province, China;Key Colleges and Universities Laboratory of Neurosurgery in Heilongjiang Province, 150001, Harbin, Heilongjiang Province, China;Institute of Neuroscience, Sino-Russian Medical Research Center, Harbin Medical University, 150001, Harbin, Heilongjiang Province, China;Department of Neurosurgery, The Pinghu Hospital of Shenzhen University, 518100, Shenzhen, Guangdong Province, China;Key Colleges and Universities Laboratory of Neurosurgery in Heilongjiang Province, 150001, Harbin, Heilongjiang Province, China;Institute of Neuroscience, Sino-Russian Medical Research Center, Harbin Medical University, 150001, Harbin, Heilongjiang Province, China;Department of Neurosurgery, The Pinghu Hospital of Shenzhen University, 518100, Shenzhen, Guangdong Province, China;North Broward Preparatory School, 7600 Lyons Road, 33073, Coconut Creek, FL, USA;

关键词: Long noncoding RNAs;    SNHG12;    TCGA;    Biomarker;   

DOI  :  10.1186/s41016-021-00250-4

来源: Springer

【 摘 要 】

BackgroundTumors are the second most common cause of death in humans worldwide, second only to cardiovascular and cerebrovascular diseases. Although methods and techniques for the treatment of tumors continue to improve, the effect is not satisfactory. These may lack effective therapeutic targets. This study aimed to evaluate the value of SNHG12 as a biomarker in the prognosis and clinical characteristics of various cancer patients.MethodsWe analyzed SNHG12 expression and plotted the survival curves of all cancer samples in the TCGA database using the GEPIA tool. Then, we searched for eligible papers up to April 1, 2019, in databases. Next, the data were extracted from studies examining SNHG12 expression, overall survival and clinicopathological features in patients with malignant tumors. We used Review Manager 5.3 and Stata 15 software to analyze the statistical data.ResultsIn the TCGA database, abnormally high expression of SNHG12 in tumor samples indicates that the patient has a poor prognosis. Results of meta-analysis is that SNHG12 high expression is related to low overall survival (HR = 2.72, 95% CI = 1.95–3.8, P < 0.00001), high tumor stage (OR = 3.94, 95% CI = 2.80–5.53, P < 0.00001), high grade (OR = 2.04, 95% CI = 1.18–3.51, P = 0.01), distant metastasis (OR = 2.20, 95% CI = 1.40–3.46, P = 0.0006), tumor size (OR = 2.79, 95% CI = 1.89–4.14, P < 0.00001), and lymph node metastasis (OR = 2.66, 95% CI = 1.65–4.29, P < 0.0001).ConclusionsOur study confirmed that the high expression level of SNHG12 is closely related to the clinicopathological characteristics and prognosis of patients and is a new predictive biomarker for various cancer patients.

【 授权许可】

CC BY